Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Lanthanum Carbonate Granule · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | - |
| Arm 2 | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule | DRUG | BAY77-1931 Granule TID for 4 days |
| Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet | DRUG | BAY77-1931 Chewable tablet TID for 4 days |
Inclusion Criteria: * Japanese male volunteers who must have given their written informed consent to participate in the study * Age is between 20 and 45 years * Body Mass Index (BMI) is between 17.6 and 26.4 kg/m2. * Volunteers who are judged by the investigators to be suitable for enrollment in th...
Lanthanum Carbonate Granule is used for hyperphosphatemia, a condition of elevated phosphate levels in the blood. It is being developed by Bayer AG as a small molecule therapy in the nephrology therapeutic area. The drug is currently in Phase 1 clinical development.
Lanthanum Carbonate Granule is being developed by Bayer AG, which trades under the ticker BAYRY. The company is conducting clinical trials for this drug in the treatment of hyperphosphatemia. The drug is currently in Phase 1 development.
Lanthanum Carbonate Granule is in Phase 1 clinical development. It is an investigational drug being studied for hyperphosphatemia. One Phase 1 trial has been completed, and the drug is not yet approved for any use.
Lanthanum Carbonate Granule has one completed clinical trial, NCT01053676, titled "Bioequivalence Study of BAY77-1931 Granule." This Phase 1 study enrolled 59 healthy male volunteers in Japan, aged 20 years and older, and was active-controlled but not double-blinded.
Yes, Lanthanum Carbonate Granule is also known as BAY77-1931. The clinical trial NCT01053676, which studied this drug, is titled "Bioequivalence Study of BAY77-1931 Granule," confirming that BAY77-1931 is the same drug as Lanthanum Carbonate Granule.